Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Analysts

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $35.67.

Several equities analysts have issued reports on the company. Leerink Partners boosted their price target on Vir Biotechnology from $18.00 to $20.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. Barclays increased their target price on shares of Vir Biotechnology from $26.00 to $31.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and issued a $110.00 price target on shares of Vir Biotechnology in a research note on Friday, February 28th. Morgan Stanley raised shares of Vir Biotechnology from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $10.00 to $20.00 in a research report on Thursday, January 9th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $19.00 target price on shares of Vir Biotechnology in a research report on Thursday, February 27th.

Insider Activity at Vir Biotechnology

In other Vir Biotechnology news, Director Vicki L. Sato sold 10,960 shares of the stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total value of $137,219.20. Following the completion of the sale, the director now owns 1,312,391 shares in the company, valued at approximately $16,431,135.32. This trade represents a 0.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director George A. Scangos sold 10,964 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total value of $107,556.84. Following the sale, the director now directly owns 708,295 shares of the company's stock, valued at $6,948,373.95. The trade was a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 30,859 shares of company stock valued at $326,458. 15.60% of the stock is owned by insiders.

Remove Ads

Institutional Trading of Vir Biotechnology

A number of large investors have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Vir Biotechnology during the 4th quarter valued at approximately $42,000. SBI Securities Co. Ltd. purchased a new position in Vir Biotechnology in the fourth quarter valued at approximately $60,000. PNC Financial Services Group Inc. grew its holdings in Vir Biotechnology by 31.8% during the fourth quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock valued at $61,000 after purchasing an additional 1,999 shares during the period. KBC Group NV increased its position in Vir Biotechnology by 136.5% in the fourth quarter. KBC Group NV now owns 8,970 shares of the company's stock worth $66,000 after buying an additional 5,177 shares during the last quarter. Finally, CIBC Asset Management Inc bought a new stake in shares of Vir Biotechnology in the fourth quarter valued at $74,000. Hedge funds and other institutional investors own 65.32% of the company's stock.

Vir Biotechnology Trading Down 1.4 %

NASDAQ:VIR traded down $0.11 on Tuesday, reaching $7.96. 839,150 shares of the stock traded hands, compared to its average volume of 2,351,715. Vir Biotechnology has a 1-year low of $6.56 and a 1-year high of $14.45. The company's 50 day moving average is $9.51 and its 200-day moving average is $8.48. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -2.03 and a beta of 1.17.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, topping analysts' consensus estimates of ($0.85) by $0.09. The business had revenue of $12.37 million during the quarter, compared to the consensus estimate of $8.14 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. On average, equities research analysts forecast that Vir Biotechnology will post -3.92 EPS for the current fiscal year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).